Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 2, 2014, Pages 178-188

  Boursier, J ^a,b   Brochard, C ^a   Bertrais, S ^b   Michalak, S ^a   Gallois, Y ^a,b   Fouchard Hubert, I ^a   Oberti, F ^a   Rousselet, M C ^a,b   Cales P ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b UMR S646   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; APRI; ARTICLE; BIOPSY DEVICE; BLOOD EXAMINATION; CAUSE OF DEATH; CIRRHOMETER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; FEMALE; FIB4; FIBROMETER; FOLLOW UP; HEMATOLOGY EQUIPMENT; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER EXAMINATION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METAVIR F; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SYNDROME DELINEATION;

ADULT; BIOPSY; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC TESTS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROGNOSIS;

EID: 84902847231     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12813     Document Type: Article

References (35)

1. Cales P, Veillon P, Konate A, et al,. Reproducibility of blood tests of liver fibrosis in clinical practice. Clin Biochem 2008; 41: 10-8.
2. EASL. Clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
3. Ghany M, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
4. Bedossa P, Carrat F,. Liver biopsy: the best, not the gold standard. J Hepatol 2009; 50: 1-3.
5. Mayo MJ, Parkes J, Adams-Huet B, et al,. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 2008; 48: 1549-57.
6. Naveau S, Gaudé G, Asnacios A, et al,. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009; 49: 97-105.
7. Parkes J, Roderick P, Harris S, et al,. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59: 1245-51.
8. Ngo Y, Munteanu M, Messous D, et al,. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006; 52: 1887-96.
9. Nunes D, Fleming C, Offner G, et al,. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 2010; 105: 1346-53.
10. Yu ML, Lin SM, Lee CM, et al,. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology 2006; 44: 1086-97.
11. Boursier J, De Ledinghen V, Zarski J, et al,. A new combination of blood test and Fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2011; 106: 1255-63.
12. Castera L, Sebastiani G, Le Bail B, de Ledinghen V, Couzigou P, Alberti A,. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010; 52: 191-8.
13. Sebastiani G, Halfon P, Castera L, et al,. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49: 1821-7.
14. Cales P, de Ledinghen V, Halfon P, et al,. Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int 2008; 28: 1352-62.
15. D'Amico G, Garcia-Tsao G, Pagliaro L,. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-31.
16. D'Amico G, Villanueva C, Burroughs AK, et al,. Clinical stages of cirrhosis: a multicenter cohort study of 1858 patients. Hepatology 2010; 52: 329A.
17. Wai CT, Greenson JK, Fontana RJ, et al,. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
18. Sterling RK, Lissen E, Clumeck N, et al,. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.
19. Adams LA, Bulsara M, Rossi E, et al,. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867-73.
20. Castera L, Vergniol J, Foucher J, et al,. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50.
21. Leroy V, Halfon P, Bacq Y, et al,. Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. Clin Biochem 2008; 41: 1368-76.
22. Boursier J, Bacq Y, Halfon P, et al,. Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol 2009; 21: 28-38.
23. Boursier J, Bertrais S, Oberti F, et al,. Comparison of accuracy of fibrosis degree classifications by liver biopsy and non invasive tests in chronic hepatitis C. BMC Gastroenterol 2011; 30: 132.
24. Poynard T, Imbert-Bismut F, Munteanu M, et al,. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004; 3: 8.
25. Harrell FE Jr, Lee KL, Mark DB,. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-87.
26. Empana JP, Tafflet M, Escolano S, et al,. Predicting CHD risk in France: a pooled analysis of the D.E.S.I.R., Three City, PRIME, and SU.VI.MAX studies. Eur J Cardiovasc Prev Rehabil 2011; 18: 175-85.
27. Vallet-Pichard A, Mallet V, Nalpas B, et al,. FIB64: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and Fibrotest. Hepatology 2007; 46: 32-6.
28. Cales P, Boursier J, Ducancelle A, et al,. Improved fibrosis staging by elastometry and blood test in chronic hepatitis C. Liver Int 2013; doi: 10.1111/liv.12327 [Epub ahead of print].
29. Thein HH, Yi Q, Dore GJ, Krahn MD,. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418-31.
30. Everhart JE, Wright EC, Goodman ZD, et al,. Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 2010; 51: 585-94.
31. Liu S, Schwarzinger M, Carrat F, Goldhaber-Fiebert JD,. Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients. PLoS ONE 2011; 6: e26783.
32. Canavan C, Eisenburg J, Meng L, Corey K, Hur C,. Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK. Dig Dis Sci 2013; 58: 2691-704.
33. Masuzaki R, Tateishi R, Yoshida H, et al,. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009; 49: 1954-61.
34. Merchante N, Riveri-Juarez A, Tellee F, et al,. Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus co-infected patients with compensated liver cirrhosis. Hepatology 2012; 56: 228-38.
35. Vergniol J, Foucher J, Terrebonne E, et al,. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140: 1970-9.